Certified by Founder Lodge
CellCentric
United Kingdom - Cambridge
START UP
1 Disclosed Funding Rounds $25,000,000
0 Participating Investments
-
Founded date
2004
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally.
p300/CBP are twin (paralogue) acetyl transferases
Pfizer
IDRx
CAMP4 Therapeutics
Delfi Diagnostics
xilis
Manifold Bio
Alchemyca Biotech | $2,500,000 | (Nov 22, 2024)
Shinami | $5,645,000 | (Nov 22, 2024)
Iontra Inc | $45,000,000 | (Nov 22, 2024)
Clean Skin Club | $32,000,000 | (Nov 22, 2024)
Lighthouse (UK) | $370,000,000 | (Nov 22, 2024)
